These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36178248)

  • 1. Evaluating the bioequivalence of two pitavastatin calcium formulations based on IVIVC modeling and clinical study.
    Wang J; Chen J; Wang L; Yang D; Shao R; Lou H; Ruan Z; Jiang B
    Clin Transl Sci; 2023 Jan; 16(1):85-91. PubMed ID: 36178248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of absorption modeling to predict bioequivalence outcome of two batches of etoricoxib tablets.
    Mitra A; Kesisoglou F; Dogterom P
    AAPS PharmSciTech; 2015 Feb; 16(1):76-84. PubMed ID: 25182387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
    Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J
    Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.
    Zhang Y; Liu H; Tang MJ; Ho NJ; Shek TL; Yang Z; Zuo Z
    AAPS J; 2021 Mar; 23(2):38. PubMed ID: 33665728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space.
    Wang M; Heimbach T; Zhu W; Wu D; Reuter KG; Kesisoglou F
    AAPS J; 2024 Jun; 26(4):69. PubMed ID: 38862807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating a Modified Apparatus to Discriminate the Dissolution Capacity In Vitro and Establish an IVIVC of Mycophenolate Mofetil Tablets in the Fed State.
    Zhang G; Sun M; Jiang S; Wang L; Tan Y; Wang L; Cheng Z
    J Pharm Sci; 2021 Mar; 110(3):1240-1247. PubMed ID: 33096138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
    Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
    Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen.
    Cámara-Martinez I; Blechar JA; Ruiz-Picazo A; Garcia-Arieta A; Calandria C; Merino-Sanjuan V; Langguth P; Gonzalez-Alvarez M; Bermejo M; Al-Gousous J; Gonzalez-Alvarez I
    Int J Pharm; 2022 Feb; 614():121415. PubMed ID: 34973409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro - In vivo correlation in the development of oral drug formulation: A screenshot of the last two decades.
    Davanço MG; Campos DR; Carvalho PO
    Int J Pharm; 2020 Apr; 580():119210. PubMed ID: 32173499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of plasma concentrations using in silico modelling and simulation approach: Case of Acebutolol.
    Bokri E; Felfel H; Bahri S
    Ann Pharm Fr; 2021 Sep; 79(5):530-538. PubMed ID: 33675740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets.
    Jaiswal S; Ahmed T; Kollipara S; Bhargava M; Chachad S
    Drug Dev Ind Pharm; 2021 May; 47(5):778-789. PubMed ID: 34082622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC.
    Ruiz Picazo A; Martinez-Martinez MT; Colón-Useche S; Iriarte R; Sánchez-Dengra B; González-Álvarez M; García-Arieta A; González-Álvarez I; Bermejo M
    Mol Pharm; 2018 Jun; 15(6):2307-2315. PubMed ID: 29746133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products Based on Physiologically Based Pharmacokinetic Modeling: An In-Depth Analysis.
    Li X; Yang Y; Zhang Y; Wu C; Jiang Q; Wang W; Li H; Li J; Luo C; Wu W; Wang Y; Zhang T
    Mol Pharm; 2019 Sep; 16(9):3780-3790. PubMed ID: 31398041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space.
    Miranda Dos Santos E; Ferraz HG; Issa MG; Duque MD
    J Pharm Sci; 2023 Dec; 112(12):3131-3140. PubMed ID: 37473918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers.
    Huang YH; Li ZQ; Pan GX; Li YF; Liu Y; Sun JX; Gu XF; Li N; Wang BH
    Clin Ther; 2014 Sep; 36(9):1205-1216.e6. PubMed ID: 25234550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
    Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Semi-Mechanistic Physiologically Based Biopharmaceutics Model to Describe Complex and Saturable Absorption of Metformin: Justification of Dissolution Specifications for Extended Release Formulation.
    Bhattiprolu AK; Kollipara S; Boddu R; Arumugam A; Khan SM; Ahmed T
    AAPS PharmSciTech; 2024 Aug; 25(7):193. PubMed ID: 39168956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
    Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
    Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help.
    Wu F; Cristofoletti R; Zhao L; Rostami-Hodjegan A
    Biopharm Drug Dispos; 2021 Apr; 42(4):118-127. PubMed ID: 33759204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.